Form 4: Karyopharm Therapeutics CEO Richard Paulson Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Richard Paulson, CEO of Karyopharm Therapeutics, sold 3,675 shares of common stock on November 5, 2024, to cover withholding tax liabilities.
Summary
- Richard Paulson, the President and CEO of Karyopharm Therapeutics Inc., sold 3,675 shares of the company's common stock on November 5, 2024.
- The sale was executed at a price of $0.9106 per share.
- The transaction was conducted under a pre-arranged automatic sale plan adopted on June 10, 2021, to cover withholding tax obligations related to the vesting of restricted stock units.
- Following the transaction, Paulson directly owns 1,131,932 shares of Karyopharm Therapeutics Inc.
- The shares were sold in multiple transactions at prices ranging from $0.9101 to $0.9350, inclusive.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to an insider stock sale for tax purposes. It doesn't convey any particularly positive or negative sentiment about the company's prospects.
Industry Context
This is a routine disclosure of an insider stock sale, common for executives to cover tax obligations related to stock-based compensation. It doesn't necessarily indicate a change in the executive's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| June 10, 2021 | Date the reporting person adopted a durable automatic sale instruction plan. |
| November 05, 2024 | Date of the transaction (stock sale). |
| November 06, 2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.